Sister Chromatid Exchange and Genomic Instability in Soft Tissue Sarcomas: Potential Implications for Response to DNA-Damaging Treatments
Table 1
Endogenous sister chromatid exchange in sarcoma cell lines.
Cell line
Histological subtype
Passage number
Number of metaphases
Chromosome count, median (range)
Median SCE count
Range
Observed
aNormalised
Nontumour/low SCE controls
hTERT-RPE1
Normal retinal epithelium
7
43 (31–48)
8
8
6–13
SOM-196b
Uveal melanoma
11
45 (34–46)
6
6
1–14
Commercially available sarcoma cell lines
U-2 OS
Osteosarcoma
30
71 (64–76)
47
31
17–63
SK-LMS-1
Leiomyosarcoma
10
100 (86–151)
42
18
14–37
SK-UT-1
Uterine leiomyosarcoma
20
44 (32–48)
14
15
8–31
SW-1353
Chondrosarcoma
12
48 (45–53)
17
16
9–20
Primary sarcoma cell lines
Shef-UPS 01
Undifferentiated pleomorphic sarcoma
p69
22
59 (44–67)
13
10
7–18
bShef-UPS 02
Undifferentiated pleomorphic sarcoma
p15
10
60 (56–60)
23
17
10–27
p30
7
89 (53–114)
24
16
7–30
bShef-UPS 03
Undifferentiated pleomorphic sarcoma
p17
29
56 (47–60)
23
18
9–33
p33
24
71 (50–126)
23
17
9–32
bShef-UPS 04
Undifferentiated pleomorphic sarcoma
p3
12
60 (51–65)
20
16
8–25
p8
30
59 (52–69)
20
15
7–30
Shef-DDLPS 01
Dedifferentiated liposarcoma
p70
29
76 (41–97)
22
13
7–21
b,cShef-DDLPS 02
Dedifferentiated liposarcoma
p12
30
108 (51–154)
35
14
9–25
p23
29
117 (52–151)
33
13
7–26
Shef-LMS 01 w1
Leiomyosarcoma
p51
25
127 (74–152)
28
10
8–20
Shef-LMS 01 ws
Leiomyosarcoma
p62
22
118 (80–134)
31
11
7–21
Shef-MFS 02
Myxofibrosarcoma
p2
15
77 (42–105)
24
15
11–26
aNormalised for 2n karyotype by multiplying observed SCE counts by 46 and then dividing by observed chromosome number. bTumour was previously treated with radiotherapy prior to resection. cSCE analysis was repeated after further in vitro culture.
